Effects of different doses of soy isoflavones on bone tissue of ovariectomized rats.
OBJECTIVE
Studies report that hormone replacement prevents osteoporosis, but there are doubts whether isoflavones are really efficient in this process. The aim of this study was to evaluate the effects of different doses of soy isoflavones on bone tissue of ovariectomized rats.


METHODS
Forty female rats at the age of 6 months were ovariectomized and, after 3 months, the animals were divided into four groups: GI - Control (treated with drug vehicle); GII - treated with isoflavones (80 mg/kg per day); GIII - treated with isoflavones (200 mg/kg per day) and GIV - treated with isoflavones (350 mg/kg per day). Soy isoflavones were administered by gavage for 90 consecutive days. After treatment, the rats were euthanized and their distal femurs were removed for histological routine, histochemistry and biochemical study. Histological sections were stained with hematoxylin-eosin or subjected to picrosirius red and alcian blue methods. Shafts of femurs were submitted to biochemical assay and tibias were subjected to biophysical and biomechanical tests.


RESULTS
In distal femurs, the trabecular bone volume was higher in the groups treated with isoflavones, being higher in GIV, while the cortical bone width and the presence of mature type I collagen fibers were higher in GII. At the trabecular bone region, the percentage of total glycosaminoglycans (GAGs) was higher in GII and the percentage of only sulfated GAGs was higher in GIII, while the higher content of chondroitin sulfate in shafts of femurs was seen in GIV. Biophysical and biomechanical tests in tibias did not differ among the groups.


CONCLUSIONS
Our data indicate that soy isoflavones improve bone quality in femurs of rats by increasing histomorphometric parameters, the content of GAGs and mature type I collagen fibers. These positive effects are dose-dependent and it was different in cortical and trabecular bone.
* Federal University of São Paulo, Morphology and Genetics , São Paulo.
M A
MA
Santos
R
R
Florencio-Silva
V P
VP
Medeiros
H B
HB
Nader
K O
KO
Nonaka
G R S
GR
Sasso
M J
MJ
Simões
R D
RD
Reginato
D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D024042:Collagen Type I / Q000378:metabolism; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D005269:Femur / Q000378:metabolism / Q000473:pathology; D006025:Glycosaminoglycans / Q000378:metabolism; D006801:Humans; D007529:Isoflavones / Q000494:pharmacology*; D010024:Osteoporosis / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D010052:Ovariectomy / Q000009:adverse effects*; D010936:Plant Extracts / Q000494:pharmacology*; D051381:Rats; D013025:Glycine max; D013977:Tibia / Q000378:metabolism / Q000473:pathology; D016896:Treatment Outcome
D024042:Collagen Type I; D006025:Glycosaminoglycans; D007529:Isoflavones; D010936:Plant Extracts
BONE; COLLAGEN; GLYCOSAMINOGLYCANS; ISOFLAVONES; RATS